Related Experiment Video
Updated: Jan 19, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
microRNA-17 functions as an oncogene by downregulating Smad3 expression in hepatocellular carcinoma
Zhufeng Lu1, Xiuhua Li2, Yongfeng Xu3
1Department of Anesthesia, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China. lu.zhufeng@zs-hospital.sh.cn.
Abstract:
The sekelsky mothers against dpp3 (Smad3) functions as a transcriptional modulator activated by transforming growth factor-β (TGF-β). Accumulated evidences indicated that Smad3 played the important roles in carcinogenesis and progression of hepatocellular carcinoma (HCC). Up to now, the regulatory mechanism of Smad3 in HCC still remains unclear. It has been known that some particular microRNAs (miRNAs) involve in carcinogenesis through the regulation of gene expressions with targeting mRNAs. In our study, the unknown candidates of miRNAs that target Smad3 mRNA were searched by using a newly established in vivo approach, the miRNA in vivo precipitation (miRIP). Using a loss-of-function assay, we demonstrated that miR-17 directly targeted Smad3 in HCC cells and inhibition on miR-17 increased Smad3 expression. Furthermore, we found that downregulation on Smad3 expression was consistent with high level of miR-17 in HCC tissues of patients when compared with around normal liver tissues. The manipulated miR-17 silence in HCC cells suppressed their growth of both in vitro and in vivo. Such suppression on cell growth could be recovered through downregulating Smad3. In addition, miR-17 affected cell proliferation through arresting cell cycle in G1 phase. The negative correlation between levels of miR-17 and protein levels of Smad3 was supported by the results of analysis with HCC tissue chip. In summary, for the first time, we confirmed that miR-17 directly targeted Smad3 mRNA and downregulated Smad3 protein expression in HCC. Our results indicated that the increased expression of miR-17 promoted carcinogenesis of HCC through down-regulations of Smad3, suggesting miR-17 might serve as the potential diagnostic and therapeutic targets for clinical HCC.
Insights
MicroRNA-17 (miR-17) directly targets Smad3 in hepatocellular carcinoma (HCC), downregulating its expression. This miR-17/Smad3 interaction promotes HCC progression, suggesting miR-17 as a potential diagnostic and therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- Smad3 (mothers against dpp3) is a TGF-β-activated transcriptional modulator crucial in hepatocellular carcinoma (HCC) development.
- The precise regulatory mechanisms of Smad3 in HCC, particularly involving microRNAs (miRNAs), remain largely unknown.
Purpose of the Study:
- To identify novel miRNAs targeting Smad3 mRNA in HCC.
- To elucidate the functional role of miR-17 in HCC pathogenesis via Smad3 regulation.
Main Methods:
- Utilized miRNA in vivo precipitation (miRIP) to discover miRNA candidates targeting Smad3 mRNA.
- Employed loss-of-function assays to validate miR-17's direct targeting of Smad3.
- Analyzed miR-17 and Smad3 expression levels in HCC patient tissues.
Main Results:
- miR-17 was confirmed to directly target Smad3 mRNA, leading to decreased Smad3 protein expression in HCC cells.
- Downregulation of Smad3 correlated with elevated miR-17 levels in HCC tissues compared to normal liver tissues.
- miR-17 inhibition suppressed HCC cell growth in vitro and in vivo by upregulating Smad3, and miR-17 induced cell cycle arrest at the G1 phase.
Conclusions:
- This study establishes miR-17 as a direct negative regulator of Smad3 in HCC.
- The findings reveal that increased miR-17 expression promotes HCC carcinogenesis by downregulating Smad3.
- miR-17 presents a promising potential biomarker for HCC diagnosis and a therapeutic target.
Related Concept Videos
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic...
Abnormal Proliferation
Experimental RNAi

